Skip to content
Medical Health Aged Care, Women

MEDIA INVITATION: Is this the next big skin treatment trend? Meet StellarM22(TM) with XPL(TM) – The Next Generation of Skin Technology Launches in Australia.

Lumenis Aesthetics Australia & New Zealand 2 mins read
Key Facts:

📍 Crown Sydney
      1 Barangaroo Ave, Barangaroo

📅 March 16

12:00 PM – 5:00 PM


Skin rejuvenation is entering a new era and those covering the future of beauty are invited to see it first-hand.

Lumenis, the global pioneers behind Intense Pulsed Light (IPL) technology, are launching StellarM22™ with XPL™ (Expert Pulsed Light) - an advanced next-generation platform designed to treat over 30 skin conditions across all skin types.

Backed by new clinical data presented at the American Society for Dermatologic Surgery (ASDS) meeting, the technology demonstrated up to 70% improvement in pigmented and vascular lesions after a single treatment session.

To mark the Australian launch, Lumenis will host an exclusive event in Sydney on March 16 at Crown, Barangaroo, offering attendees a first look at the technology shaping the future of non-invasive skin treatments.

Attendees will have the opportunity to:

• Hear from leading aesthetic experts and practitioners

• Discover emerging trends shaping the global aesthetics industry

• Learn about the clinical science behind StellarM22™ with XPL™

• Experience a first-hand look at the technology behind some of today’s most in-demand skin treatments

Already installed in thousands of clinics worldwide, the M22 platform has become one of the most trusted technologies in aesthetic dermatology.

The new StellarM22™ with XPL™ introduces advanced Expert Pulsed Light technology, designed to deliver faster treatments, greater precision, and improved patient outcomes.

RSVP / Media Enquiries

To register or confirm attendance, please contact:

Kate Boissett
Head of Marketing – Lumenis Aesthetics
0422 734 622
kate.boissett@lumenis.com

 


Contact details:

Kate Boissett
Head of Marketing – Lumenis Aesthetics
0422 734 622
kate.boissett@lumenis.com

Media

More from this category

  • Medical Health Aged Care
  • 15/04/2026
  • 06:00
Monash University

New research shows a free online tool could improve opioid safety for millions of Australians

New Monash University research has found that a free, interactive online tool can help people taking prescription opioids for pain to better understand their risks and adopt safer behaviours, more than doubling requests for naloxone, a medicine that reverses opioid overdose. Opioids have remained the leading cause of drug-induced deaths in Australia for over two decades, with two-thirds of opioid-related fatalities involving prescription opioids. An estimated 4 out of 5 people prescribed opioids for chronic pain have at least one overdose risk factor, yet many have limited understanding of these risks. Previous research has found that only an estimated 2…

  • Medical Health Aged Care
  • 14/04/2026
  • 22:11
Samsung Bioepis Co., Ltd.

Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate

INCHEON, Korea–BUSINESS WIRE– Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis’s first novel…

  • Contains:
  • Medical Health Aged Care
  • 14/04/2026
  • 21:10
Wellgistics Health, Inc.

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations Integrated platform accelerates pharmaceutical access, fulfillment, and commercialization Combined ecosystem provides potential…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.